Objective To develop a risk scoring system (RSS) for predicting recurrence in women with borderline ovarian tumours (BOTs).
Introduction
Borderline ovarian tumours (BOTs) are defined as the presence of atypical epithelial proliferation without stromal invasion, and represent 10-15% of all epithelial ovarian tumours. 1 From an epidemiological point of view, BOTs differ from ovarian carcinomas by a younger age at diagnosis (10 years earlier) and a better overall survival rate.
Indeed, the 5-and 10-year survival rates for stage-I, -II, and -III disease are 99 and 97, 98 and 90, and 96 and 88%, respectively. 1, 2 Despite this favourable prognosis, some patients belonging to an ill-defined high-risk group do relapse. The recurrence rate is widely variable (up to 40%), and is reported to be time dependent. [2] [3] [4] Many factors have been suggested to be correlated with a risk of recurrence, such as a younger age, the International Federation of Gynecology and Obstetrics (FIGO) stage, the preoperative CA125 serum level, the presence of invasive peritoneal implants, residual disease after surgery, the presence of micropapillary patterns in serous BOTs, the presence of intraepithelial carcinoma in mucinous lesions, the presence of stromal microinvasion in serous tumours, and the use of cystectomy in mucinous BOTs. 1, 5 The past decade has been marked by important advances in treatment options, which have created a shift in the medical decision process. Currently, the clinician needs to take into account imaging techniques, treatment options to preserve fertility, new reproductive techniques, and the woman's quality of life. Such a combination of factors renders clinical decision-making difficult, even confusing at the individual level. To overcome such limitations, a new paradigm has emerged based on the implementation in clinical practice of predictive, personalised, preventive, and participatory models. 6, 7 Hence the current therapeutic challenge for BOTs lies in distinguishing women at low risk of recurrence from those at high risk of recurrence, in order to promote a personalised therapeutic strategy including conservative management and fertility preservation surgery.
We performed this French multicentre collaborative study to develop a risk scoring system (RSS) to stratify the recurrence risk in women with BOTs as an evidence-based tool for patient classification and selection.
Methods

Study population
We conducted a retrospective analysis of a multicentre prospective database study using data from patients with BOTs who had received primary surgical treatment from January 1980 through to December 2013 at four institutions in France (Tenon University Hospital, Institut Gustave Roussy, Tours University Hospital, and Poitiers University Hospital).
The following parameters were recorded for each woman: age, preoperative serum CA125, type of surgery, completeness of surgery, fertility-sparing surgery, surgical route (laparoscopy or laparotomy), performance of lymphadenectomy, final histological subtype (serous or mucinous), FIGO staging, occurrence of a recurrence, duration of follow-up, and overall survival. Fertility-sparing surgery (conservative treatment) was defined as the preservation of the uterus and at least part of one ovary (i.e. cystectomy and unilateral salpingo-oophorectomy, USO). Surgical treatment was considered non-conservative when bilateral salpingo-oophorectomy (BSO) was performed or when an USO was performed in women with prior contralateral adnexectomy, with or without hysterectomy. In line with current French guidelines, 8 the initial surgical staging was considered complete when all peritoneal surfaces had been carefully inspected with peritoneal washing, random or oriented multiple biopsies performed, and after infracolonic omentectomy. Systematic appendectomy was also a criterion for the complete staging of mucinous BOTs. Initial surgical staging was considered incomplete in all other cases, independently of the non-conservative or conservative nature of the surgery. Histological typing was performed according to the system developed by the World Health Organization. 9 Histological slides and reports of all patients were reviewed by expert pathologists (Arbion F, Cortez A, and Duvillard P) with homogeneous histological criteria. All cases had centralised histological review of the primary ovarian tumour (and of recurrent disease, in the case of relapse) by the local reference expert pathologist, using similar and homogeneous pathological criteria. Follow-up consisted of a physical examination and the use of ultrasonography and measurement of serum tumour markers. Follow-up sessions were conducted every 6 months for the first 2 years, and once a year thereafter.
Statistical analysis
Development of the RSS Disease recurrence was diagnosed by surgery and defined as a relapse without differentiating between a BOT or an invasive tumour. The main outcome measure was recurrencefree survival (RFS). Multivariate Cox proportional hazards models included demographics, and histological, surgical, and biological factors that were first tested individually for association with recurrence using univariate analysis. Factors with P ≤ 0.1 in univariate analysis and those with a demonstrated clinical correlation with recurrence were then included in the Cox proportional hazard multivariate model. The final model equation was then designed to calculate patient-specific probabilities of recurrence. Missing values in the predictors were multiply imputed with chained equations (MICE) before statistical analyses, to avoid the deletion of potentially important information and the introduction of selection bias if only complete cases were used for the analysis. 10, 11 The linear predictor of the multivariate Cox analysis was used to compute a risk score after scaling and dividing the beta coefficient by 0.4 to ease calculations. A score of 0 was allocated for the variables where a woman had an opposite result. The total score for each woman represented the sum of scores for each risk factor.
The predictive accuracy of the Cox multivariate model was assessed according to its discrimination (i.e. the ability of the model to differentiate women with recurrence from women without recurrence). To measure discrimination by the RSS, the concordance index (C-index) was used, which is an adaptation of the area under the curve (AUC) for censored data, and is mandatory when time-to-event data are used. [12] [13] [14] Optimal threshold of the RSS The optimal threshold (cut-off points) of the RSS in terms of clinical utility, sensitivity, specificity, negative predictive values (NPVs), positive predictive values (PPVs), and its overall diagnostic accuracy (i.e. probability for a woman to be correctly classified by the RSS) was evaluated by the receiver-operating characteristics (ROC) curve area and the Youden index. 15 Validation of the RSS An internal validation of the accuracy selection from the RSS was performed with 200 bootstrap resamples to obtain a relatively unbiased estimated concordance probability. The bootstrapping method is based on a resampling obtained by randomly drawing and replacing data from the original data set. 16 It provides an estimate of the average optimism of the AUC-ROC.
Recurrence events and recurrence-free survival (RFS)
For the survival analysis, data on surviving women without disease recurrence were censored on the date of their last follow-up examination. Survival curves were generated (in months) using the Kaplan-Meier method, based on the interval from the date of diagnosis to the date of last contact or recurrence. The difference in RFS was assessed by a log-rank test.
Other statistical analyses
An optimal cut-off for preoperative CA125 serum tumour markers was determined by a minimal P value approach. This necessitated dichotomising the preoperative CA125 serum tumour marker into a dummy variable with a cutoff at every 1 unit. Chi-square tests comparing the rate of women with or without recurrence for every dummy variable were then calculated, and the cut-off with the minimal P value was chosen as the optimal cut-off.
The categorical and numerical variables were analysed using the chi-square test and the Student's t-test, respectively. P < 0.05 was considered to denote a significant difference. Data were managed with an EXCEL database (Microsoft, Redmond, WA, USA) and analysed using R 2.15, available online with rms, presence/absence, MICE, and verification libraries.
Results
Characteristics of the study population
During the study period, 360 women with BOTs were documented as having received primary surgical treatment according to the following distribution: Tenon University Hospital and Institut Gustave Roussy (n = 186; 51.67%), Tours University Hospital (n = 143; 39.72%), and Poitiers University Hospital (n = 31; 8.61%). The demographics and clinicopathological characteristics of the whole cohort are reported in Table 1 . The median age of the women was 39 years (range 14-89 years). The recurrence rate in the whole population was 20.0% (72/360). 
Derivation of the risk model for recurrence
The optimal preoperative CA125 serum tumour marker with the strongest correlation between preoperative CA125 serum tumour marker and recurrence status was 150 IU/ mL: 12/32 (37.5%) women with CA125 ≥ 150 IU/mL experienced a recurrence, compared with 20/134 (14.9%) women with CA125 < 150 IU/mL (P = 0.0014; Table 1 (Figure 1 ). The risk score of each predictor was assigned by dividing the beta coefficient from the Cox proportional hazard multivariate model by 0.4 (Table 2 ). Cystectomy surgery was given the highest score (6 points) and age <45 years and other FIGO stages were given the lowest score (1 point). The final scores ranged from 0 to 12. Table 3 displays the risk score for each significant factor of the RSS.
Optimal threshold of the RSS
According to the recurrence distribution at each total score of the RSS, two groups were identified: a low-risk group (<8 points, n = 297, recurrence rate 11.8%, 35/297) and a high-risk group (≥8 points, n = 63, recurrence rate 58.7%, 37/63). A total score ≥8 corresponded to the optimal threshold of the RSS in terms of clinical utility, with an overall diagnostic accuracy of 85.03%. At this threshold, the sensitivity, specificity, predictive positive, predictive negative, and overall accuracy values of the RSS were 56.45, 92.67, 65.81, 68.02, and 85.03%, respectively. Women with a total score of ≤3 points have such a low recurrence rate (<2%) that no follow-up is a reasonable option. Women with a total score ≥10 points have a high recurrence rate (88% in the case of cystectomy and 75% in the case of USO), and should have more extensive surgery discussed with them, although it may be reasonable to delay surgery until after fertility is no longer required.
Validation of the RSS
In internal validation, the 200 repetitions of bootstrap sample corrections of the RSS gave an estimated concordance probability of 0.82 (range 0.80-0.84).
RFS and overall survival according to the RSS optimal threshold
The median follow-up and initial recurrence times were 60 (range 1-320) and 50 (range 1-320) months, respectively. For each subgroup of the RSS, the median follow-up and initial recurrence times were 55.0 (range 1-316.9), 70.2 (1-316.9), 75.2 (36.6-320), and 47.0 (1-256) months, for the low-and high-risk groups, respectively (Figure 2A) .
The 5-year RFS rates were 91.8% (95% CI 87.5-96.3%) and 48.0% (95% CI 35.8-64.3%) for the low-risk and highrisk groups, respectively (P < 0.0001; Figure 2A ). Recurrence-free survival rates for the whole population and according to histology subtype are presented in Figure 2B , C.
Recurrences were diagnosed in 9.3% (18/193) of women in the BSO group, 26.0% (25/96) in the USO group, and 41.4% (29/70) in the cystectomy group. Of the women with mucinous BOTs, 8.3% experienced recurrence. Recurrence rates for this histological subtype were 1.4, 16.7, and 8.3%, respectively for BSO, USO, and cystectomy. Several reasons explain the high recurrence rate in the USO group when compared with cystectomy for mucinous subtype: first, USO patients were younger at diagnosis (mean age 31.6 versus 35.2 years), and second, they had a longer follow-up (mean 45 versus 12 months) than women with cystectomy. Of women with serous BOTs, 30.2% experienced recurrence. Recurrence rates for serous BOTs were 13.93, 41.67, and 76.47%, respectively for BSO, USO, and cystectomy. For the whole population, overall survival was 100% (95% CI 97.0-100%) at 5 years and 94.7% (95% CI 88.2-98.3) at 10 years.
Discussion
Main findings
In the current study we developed an RSS to predict the risk of recurrence in women with BOTs, focusing on a risk-grouping method in particular, to select patients for treatment strategy. The strength of this RSS lies in its ability to identify two subgroups of patients at low and high risk for recurrence.
With the abundance of new options in treatment modalities and fertility preservation, a shift in the medical decision process for BOTs has been observed. 17 The emergence of individualised medicine and the increasing complexity of the available medical data for BOTs have led to the development of several prediction models in the last decade. Although these models allowed for the stratifying and subgrouping of patients, various questions such as the optimal surgical staging as well as the assessment of recurrence have remained unanswered. In this specific setting, Obermair et al. developed a statistical model predicting the probability of recurrence in women who undergo surgery for BOTs. 18 The external validation study performed to assess the robustness of the model has suggested that there is limited generalisability to an independent population, however. 19 Similarly, Wu et al. developed a model predicting 5-year RFS with stage II/III (or invasive implants), cystectomy, and higher preoperative serum CA125 as independent variables. 20 Their recurrence-predicting model was not externally validated, however, representing a crucial limitation for its application in routine practice. More recently, Bendifallah et al. reported a nomogram that may guide the decision-making process towards the most adapted treatment options or follow-up strategies, 21 but to date it has not yet been externally validated. Although these nomograms are based on a strong methodology, using multicentre data and clinically relevant variables, it seems important to underline that no optimal thresholds have been suggested to help in clinical decision-making. Thus, the added value of the RSS that we present here lies in its ability to both deliver individualised stratification and to establish a threshold for women at high risk of recurrence (i.e. total score ≥8 points), for whom completion surgery including contralateral salpingo-oophorectomy could be indicated if the initial surgery was conservative.
The decision to perform fertility-sparing surgery in women with a BOT is mainly based on simple criteria, such as the woman's age, histological subtype, the desire to preserve childbearing potential, and the characteristics of peritoneal implants, but without clearly informing the women about their individual risk of recurrence. In the current study, the recurrence rate was 9.3, 26.0, and 41.4% for BSO, USO, and cystectomy, respectively, and was higher for serous *By Cox multivariate analysis. All variables entered a determined using five variables. [26] [27] [28] [29] the majority of authors consider that cystectomy is a suitable option because the recurrence is almost exclusively borderline in nature, and is sometimes accessible to a second conservative surgery without compromising the overall survival rate. 4, 27, 28, 30 In the case of bilateral serous BOTs, a prospective randomised trial showed that bilateral cystectomy compared with USO on the larger BOTs with contralateral cystectomy was associated with a higher pregnancy rate with no difference in the cumulative recurrence rate. 31, 32 Recently, Vasconcelos et al. confirmed the absence of difference in recurrence rate for bilateral serous BOTs between bilateral cystectomy and USO with contralateral cystectomy in a large series. 27 
Strengths and limitations
The strengths of our study lie in its multicentre nature and the large number of women included. In addition, we assessed an optimal threshold score according to its overall accuracy. Some limitations must be noted, however. First, we cannot exclude an inherent selection bias linked to large multicentre tertiary referral centres. Second, the retrospective nature of the study cannot exclude any bias, especially concerning the issue of underestimating the recurrence rate as many recurrences can occur late (>20 years). Third, we excluded rare histological subtypes such as endometrioid, Brenner, and clear-cell BOTs because of their rarity. Fourth, our RSS did not take into account some histological characteristics such as the presence of microinvasion, the mucinous subtype (intestinal versus seromucinous), the presence of intraepithelial carcinoma in the case of mucinous BOTs, or the presence of microinvasion or papillary patterns for serous BOTs. The review of BOTs conducted by Morice et al. underlines the absence of a clear relationship between these histological characteristics and the risk of recurrence, however, except in women with peritoneal implants, which corresponds to advanced-stage disease. 1 Fifth, we did not distinguish borderline from invasive recurrence. Sixth, external validation is usually required as the gold standard to evaluate the reproducibility and generalisability. It is important to note, however, that the present study is one of the largest series on recurrence after BOT treatment, thereby rending external validation on smaller series questionable. We hypothesised that, to be clinically relevant for routine practice, internal validation should be performed to allow an illustration of the discriminative ability and higher generalisability of the model. The risk of such approach is multi-collinearity where two or more predictors in a multiple regression model are highly correlated, meaning that one can be linearly predicted from the others with a non-trivial degree of accuracy. The internal validation study provided an error estimate, however, which demonstrated that the model was accurate. Nevertheless, this point needed to be confirmed by an external validation study.
Finally, the major limit, also observed in all series of women with BOTs, is the lack of preoperative evaluation of ovarian reserve assessed by a sonographic antral follicle count and the serum determination of anti-Mullerian hormone (AMH) that could have an impact on the surgical strategy.
Interpretation, in light of other evidence
Our RSS can help the clinician in decision-making by including the evaluation of recurrence risk. Based on our RSS, young women with mucinous BOTs at FIGO stage IA and preoperative serum CA125 < 150 IU/mL treated by cystectomy are at low risk of recurrence. Indeed, in the current study, 8.3% of women with mucinous BOTs experienced recurrence. Recurrence rates were 1.40, 16.67, and 8.33% for BSO, USO, and cystectomy, respectively. This result raises the issue of conservative treatment based on cystectomy for mucinous BOTs to preserve fertility. This option appears suitable as, in accordance with a review on BOTs, the risk of recurrence as an invasive lesion not only appears low but also recurrence occurs later, allowing a fertility window and the possibility of completing the surgery after a pregnancy. 1, 17 Another issue concerns the management of patients with bilateral serous BOTs who are considered at high risk of recurrence according to our RSS. Although the cumulative recurrence rate was similar in the Palomba trial between bilateral cystectomy and USO with contralateral cystectomy groups, women treated by bilateral cystectomy had a shorter time to the first recurrence (16 months) and a higher rate of radical surgery for the recurrence. These data suggest that an assisted reproductive technique should be initiated rapidly after conservative management of bilateral serous BOTs, including in vitro fertilisation (IVF) or cryopreservation of oocytes and of ovarian tissue. Finally, our RSS helps to clarify the modalities of follow-up by identifying patients at high risk of recurrence who may benefit from closer follow-up.
Conclusion
In conclusion, this RSS could be useful in clinical practice, especially concerning the issues of conservative management and secondary surgery. External validation is now required to evaluate a level of evidence in terms of generalisability; however, a key issue for risk stratification in women with BOTs remains the identification of risk factors for invasive recurrence.
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